Access to Information Requests Completed - March 2015

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of March 2015
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2012-00821 All documents related to wind energy, and correspondence between Health Canada and any representative and/or employee of Natural Resources of Canada. (Jan 1, 2002 to Aug 8, 2012). All disclosed

2,116

A-2012-01315 Information related to the names of all persons who have met with Sandra Buckler, Chief of Staff to the Minister of Health, minutes and reports concerning such meetings. (Dec 3, 2012 to Dec 11, 2012). Disclosed in part

533

A-2013-00023 Any document held by the Minister of Health on counterfeiting, i.e. products such as fake Botox and fillers (Juvederm and Restylane) and other products often illegally imported and offered at discount prices. (Apr 8, 2011 to Apr 8, 2013). Disclosed in part

37

A-2013-00100 Correspondence related to warning letters to the advertising sponsor and/or broadcaster, correspondence requesting immediate cessation of the advertisement, contacting and/or referral to the Advertising Preclearance Agencies, issuance of a risk communication, created by Health Canada’s Marketed Health Products Directorate and directed to advertising sponsors of direct-to-consumer advertising of prescription and Schedule D drug advertising. (Apr 1, 2012 to Mar 31, 2013). Disclosed in part

18

A-2013-00440

Obtain a complete copy of all the studies and statistics that have been targeted in response to a previous request with the following file reference: “5-year Forecast of Non Insured Health Benefits expenditures using cost driver modeling methodology.” (2012).

All disclosed

14

A-2013-00441

Obtain a complete copy of all the studies and statistics that have been targeted in response to a previous request with the following file reference: “Over-The-Counter (OTC) drugs project: two budget impact studies answering ‘what-if’ scenarios”.

All disclosed

33

A-2014-00043 Any documentation relating to the licensing and approval process of Mozi-Q (DIN-HM 80031902) Records should include but not be limited to product license applications, all clinical trials, all evidence submitted for approval process, all homeopathic references to traditional use, all evidence submitted for efficacy, and all evidence submitted for safety. Disclosed in part

137

A-2014-00172 All communications between Health Canada and Tweed Marijuana Inc. and Mettrum Ltd. (Mar 1, 2014 and May 5, 2014). Disclosed in part

490

A-2014-00385 Adverse Reaction Report (AER) for report numbers: 000544049, 000544256, 000544263, E2B_00014607, 000544786, 000544339, 000544326, E2B_00013471, 000544324, 000544308, 000544348, 000544335, 000544303, 000554891, 000544316, E2B_00016979. Disclosed in part

161

A-2014-00424 Correspondence and/or submission between Health Canada and any applicant or prospective applicant under the Marihuana for Medical Purposes Regulations concerning the prospective licensing of a marihuana production site at 1668 Foster’s Wasy in Delta, British Columbia. Applicants may include persons or companies. (Mar 1, 2013 to Jul 29, 2014). Disclosed in part

140

A-2014-00549

Correspondence between Health Canada Atlantic regional staff and Woodstock First Nation and documents prepared in response to emergency/crisis in Woodstock First Nation (New Brunswick) as a result of post tropical storm Arthur on July 5, 2014.

Disclosed in part

150

A-2014-00814 Copy of all communication between Health Canada and the two adjudicators with regard to Tender Notice 1000154130 (Occupational Therapist), as well as the combined technical and financial evaluation documents of Multi Options Nursing. (Jan 7, 2014 to Oct 16, 2014). Disclosed in part

556

A-2014-00895 All correspondence between Health Canada and Alberta Health on Provital Health & Wellness. (Jan 1, 2012 to Nov 3, 2014). Disclosed in part

24

A-2014-00939 Adverse Reaction Report (AER) for DEXILANT (dexlansoprazole). Report numbers: 000580649, 000585408, 000585933, 000586462, 000587001, 000589725, 000592282, 000594871, 000602553, 000603531, 000610552, 000611423, 000612294, 000613817, and 000615745. Disclosed in part

35

A-2014-00953 Documents under the Marihuana for Medical Purposes Regulations (MMPR) with Zenabis and/or its representatives. (Nov 1, 2013, to Nov 1, 2014). Disclosed in part

136

A-2014-01007 Information on the expected and/or actual total dried cannabis production capacity by licensed medical marihuana producer under the Marihuana for Medical Purposes Regulations. (Jun 1, 2013, to Nov 17, 2014). Disclosed in part

2

A-2014-01012 Information regarding the medical device Nova T, Essure, Betacomfort injector, Amikacin Inhaler, by Bayer Inc. (Jan 1, 2013 to Oct 1, 2014). Disclosed in part

61

A-2014-01030

Copy of  briefing materials:
- 14-003370-153: Flavoured tobacco product
- 14-107703-208: Chinese Engagement for NHPD
- 14-109044-903:  Advisory Council on Traditional Chinese Medicine Meeting March 2014
- 14-004827-775: Utilisation des pesticides: toxicité des néonicotinoïdes sur les abeilles
- 14-110416-285: Statistics Canada article “Inuit Health: Selected Findings from the 2012 Aboriginal Peoples Survey
- 14-108173-84: Member of Parliament (MP) request: Product Safety Recall – Table Saw From Dewalt
- 14-108102-20: MP Request: Aboriginal Head Start Program
- 14-108567-36:  MP Request: Inuit Health Survey 2007-08
- 14-108737-345: MP Request: Mouse Poison Contract
- 14-109096-703: Issues management. report: July 16 The Assembly of First Nations is planning a letter writing campaign in opposition to the First Nations and Inuit Component of the Federal Tobacco
- 14-109092-640: Issues Management Report re First Nations Food, Nutrition and Environment Study
- 14-109611-751: Overall Engagement Strategy re: Traditional Chinese Medicine
- 14-107393-469: First Nations and Inuit Health Branch (FNIHB) Senior Assistant Deputy Minister (SADM) Monthly Meeting with Minister Office (MO) August 2014
- 14-109755-4: Risk Communications Posting Process for Adverse Drug Reactions and Background on Procedures
- 14-110237-595: MP Request: Rat Poison Devolin
- 14-110239-229: MP Request: Medicinal Chinese Herb KB-C no longer available in Canada
- 14-110343-314: MP Request: Remote Area Dental Program
- 14-110889-949: MP Request: Aboriginal Head Start Program
- 14-107394-675: FNIHB A/SADM Monthly Meeting with MO Sept 2014
- 14-004178-359: Invitation to 4th Annual First Nations Health Managers Association In Vancouver Sept 2014
- 14-004370-224 : Invitation to Canadian Patient Safety Week, Edmonton October 2014
- 14-004631-737 : Invitation to 7th Annual Gathering Wisdom for a Shared Journey Conference in Vancouver May 2014
- 14-004665-765 : Request meeting on Health Crisis in Attawapiskat
- 14-005511-422 : Invitation to speak at Aboriginal AIDS Awareness Week lunch in Regina Sep 2014

Disclosed in part

172

A-2014-01052 Adverse Reaction Report (AER) for Mavik. Report numbers: 000613830 and 000601742. Disclosed in part

10

A-2014-01065 Letter issued prior to January 16, 2012 from Therapeutic Products Directorate to Q-Gen Pharmaceuticals (Q-Gen) certifying that the examination of Q-Gen-Atorvastatin (Atorvastatin Calcium) was complete. Disclosed in part

1

A-2014-01072 Letter issued prior to May 19, 2010 from Therapeutic Products Directorate to Pharmascience Inc. (Pharmascience) certifying that the examination of PMS-Atorvastatin (Atorvastatin Calcium) was complete. Disclosed in part

2

A-2014-01084 Documents related to the Marihuana for Medical Purposes Regulations (MMPR) policies or procedures for processing licensed producer applications. (Jul 1, 2014 to Dec 1, 2014). Disclosed in part

51

A-2014-01105 All documents related to the number of "Ready to Build" letters issued to Marihuana for Medical Purposes Regulations (MMPR) License applicants and number of applicant facility inspections. (June 1, 2013 to Dec 4, 2014). Disclosed in part

10

A-2014-01106 Documents pursuant to the Marihuana for Medical Purposes Regulations (MMPR) such as policies/procedures for processing applications, advertising restrictions, delays in processing application, timing of granting licences or the maximum anticipated number of licences, inspection policies/procedures, security clearance application, refusal of applications. (Jun 1, 2013 to Dec 4, 2014) Disclosed in part

166

A-2014-01119 Adverse Reaction Report (AER) for Lantus (insulin glargine). Report number: 000605550. Disclosed in part

3

A-2014-01121 Adverse Reaction Report (AER) for Lovenox (enoxaparin sodium). Report number: E2B_00081618. All disclosed

23

A-2014-01125 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00087846. All disclosed

10

A-2014-01128 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00093546. All disclosed

11

A-2014-01129 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00110290. Disclosed in part

73

A-2014-01130 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00094974. All disclosed

53

A-2014-01172

Copies of the following briefing materials provided to the Deputy Minister, listed by Ministerial Executive Correspondence System number:
- 14-110416-285:  Release of Statistics Canada the  2012 Aboriginal People Survey
- 14-109798-801:  2016 United Nations General Assembly Special Session on World Drug Problem

Disclosed in part

94

A-2014-01183 Information pertaining to age, sex, income, illness, dosage and preferences for the average consumers based under the Marihuana for Medical Purposes Regulations (MMPR) program. All disclosed

4

A-2014-01197 A list of all briefing materials in any medium, prepared for the Minister and/or Deputy Minister for December 2014. Disclosed in part

10

A-2014-01228 A list of all briefing material provided to the Minister in November 2014. Disclosed in part

6

A-2014-01229 A list of all briefing material provided to the Deputy Minister in December 2014. Disclosed in part

10

A-2014-01237 Documents reviewed by the Pest Management Regulatory Agency (PMRA) in the course of its evaluation of available scientific information related to the aspects of concern and used by or relied on by PMRA in arriving at its conclusion that registered products containing “quintozene” do not pose unacceptable risks to human health or the environment as stated under the section 6 at page 3 of Re-evaluation Note (REV2014-07) Special Review of “Quintozene: Proposed Decision for Consultation”, which was published on Health Canada's website on December 18, 2014. All disclosed

17

A-2014-01241

Information related to the database used by the Office of Controlled Substances, to track substances/materials that have been reviewed to determine whether or not they are controlled under the Controlled Drugs and Substances Act.

All disclosed

80

A-2014-01291 The toxicology reports of studies that Health Canada used for its safety evaluation of “morpholine” in waxed apples in 2002, including studies conducted and/or contracted by Health Canada, and any relevant published reports. All disclosed

6

A-2014-01301 Documents related to Health Canada’s working group on complaints regarding long waiting time for health care services. (Jul 1, 2014 to Jan 29, 2014). No records exist

0

A-2014-01315 Adverse Reaction Report (AER) for report number: 000614641. Disclosed in part

7

A-2014-01322 Information related to Health Canada’s Advisory Council on Traditional Chinese Medicines membership since its creation in 2012. All disclosed

1

A-2014-01331 All communications related to James McNamee’s City of Chateauguay court hearings testimony on Roger’s proposed cell tower siting about November 2011 and about February 2012 and including communications which followed the testimony. All disclosed

57

A-2014-01351 Information related to the results of radon values of government buildings in Canada. Disclosed in part

4,000

A-2014-01356 Documents related to the Marihuana for Medical Purposes Regulations (MMPR) reporting dashboard for application processing and licensing activities along with the form Application to Become a Licensed Producer Under the MMPR stamped by the Office of Controlled Substances and copies of Producer Licences issued for Bedrocan Canada Inc., Mettrum Ltd., Tilray, Tweed Inc. and Whistler Medical Marijuana Corp. (Oct 31, 2014 to Dec 31, 2014). All disclosed

3

A-2014-01366 All call-ups or contracts processed by this institution in the Western, Pacific and Greater Toronto regions under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of Aug. 1, 2014 to Dec. 31, 2014. Disclosed in part

25

A-2014-01367 All call-ups or contracts processed by this institution in regions other than Western, Pacific and Greater Toronto Area under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of Jan. 1, 2014 to Dec. 31, 2014). All disclosed

10

A-2014-01370 All documents relating to Safety Code 6, MD symposium and Private member’s Bill C-648  and only to and from James McNamee (acting or otherwise) regarding media conference (Jul 9, 2014), public consultation (Jul 15, 2014), symposium on health issues (Sep 12, 2014), media conference (Jan 19, 2015) (Jul 1, 2014 to Feb 11, 2015) No records exist

0

A-2014-01371 Adverse Reaction Report (AER) for “Aldara”, “Aldara 5% Cream” or generic name Imiquimod. Reports from Jan. 1, 1997 to Feb 11, 2015. All disclosed

4

A-2014-01380 Documents regarding the drug “Aldara, Aldara 5% cream” or its generic name Imiquimod, to confirm or to disprove the potential association between the drug and adverse reaction. (Jan 1, 1997 to Feb 12, 2015). All disclosed

35

A-2014-01381 Information related to the Medical Marihuana Access Regulations (MMAR) especially the number of plants allowed for users to keep on their property and statistics on the number of production permits, that were granted under the program, that identify the number of plants each permit allows by province and in all the country Disclosed in part

6

A-2014-01388 Documents related to expenses, including receipts, submitted by or for Parliamentary Secretary Eve Adams. (Apr 1, 2014 to Feb 16, 2015). Disclosed in part

24

A-2014-01391 Correspondence sent or received by Eve Adams, Parliamentary Secretary to the Minister of Health. (Feb 1, 2015 to Feb 10, 2015). No records exist

0

A-2014-01403 All checklists that are used to evaluate MMPR applications from the start of the program to those that are currently used. Disclosed in part

166

A-2014-01404 Adverse Reaction Report (AER) for Iovate. Report numbers: 000618290 and 000626171. Disclsoed in part

6

A-2014-01405 Documents related to any consumer product complaints with respect to incidents involving Poliris Sportsman 850 XP ATV’s causing personal injuries. (Jul 7, 2003 to Feb 12, 2015). Disclosed in part

7

A-2014-01417 Adverse Reaction Report (AER) for report numbers: 00606080, 00615267, 00625971, 00620490, 00551926, 00439803, 00507337 and 00428601. Disclosed in part

11

A-2014-01431 Copy of the report: Re-evaluation of Citronella Oil and Related Active Compounds for Use as Personal Insect Repellents (PACR2004-36) of Sep 17, 2004. All disclosed

35

A-2014-01432 Information concerning the Government of Canada review of the Regulatory Approach for Personal Insect Repellents Containing Plant-Derived Essential Oils dated December 3, 2014, related to the costs associated, name of the selected members of the external review panel, and information concerning the March 16, 2006 review panel for the safety of Methyl Eugenol resulting in the report “Report of an Independent Science Panel on Citronella Oil used in an Insect Repellant. Disclosed in part

34

A-2014-01436 Information related to the total number of prescriptions filled for medical supplies and equipment (MS&E) under the Non Insured Health Benefits Program in Manitoba, with prescription orders for medical supplies separate from prescription orders for equipment by pharmacies versus medical supply companies; and, MS&E orders filled in Winnipeg and Brandon versus all other parts of Manitoba. (Apr 1, 2013 to Mar 31, 2014). All disclosed

1

A-2014-01437 Information related to the total number of prescriptions (excluding medical supplies and equipment) filled under the Non Insured Health Benefits Program in Manitoba, with prescription filled urban centres of Winnipeg and Brandon versus prescription filled outside these centres; and, average dispensing fee charged in the province for prescriptions containing “metformin” 500 mg. (Apr 1, 2013 to Mar 31, 2014). All disclosed

1

A-2014-01443 Information on the Roman Catholic Hierarchy - Controversial Matters, located in File Block 602-6-7, Iesous Hominem Salvator (I.H.S) and any associated records No records exist

0

A-2014-01446

All communications of James McNamee regarding Private members Bill C-648 – Warning Labels for Radio Apparatus Act commonly called the cell phone labelling bill, including the press conference held by Member of Parliament (MP) and Canadians for Sage Technology on January 19 and meetings with MPs of February 23rd and 24th, 2015. (Jan 22, 2015 to Mar 6, 2015)

No records exist

0

A-2014-01465 Information on a Property Transfer Assessment for seven properties located in the Municipality of Leamington, County of Essex and related to health issues associated with the properties or in the immediate vicinity of the properties. No records exist

0

A-2014-01466 All correspondence and documents relating to, used in or considered in the review, approval and listing of Lignin Sulfonate (in any form, including condensed and dehydrated) as a feed ingredient for animals. No records exist

0

Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: